Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7241761 | 1.00 | SLC6A3 (0.42) | SLC6A3 | |
| SCHEMBL7314846 | 0.92 | SLC6A3 (0.48) | SLC6A3 | |
| SCHEMBL7421806 | 0.92 | SLC6A3 (0.48) | SLC6A3 | |
| SCHEMBL8602315 | 0.92 | SLC6A3 (0.48) | SLC6A3 | |
| SCHEMBL8602312 | 0.92 | SLC6A3 (0.48) | SLC6A3 | |
| SCHEMBL7314835 | 0.92 | SLC6A3 (0.48) | SLC6A3 | |
| SCHEMBL6603181 | 0.90 | CYP2D6 (0.46) | SLC6A3 | |
| SCHEMBL6598452 | 0.90 | CYP2D6 (0.46) | SLC6A3 | |
| SCHEMBL6598457 | 0.90 | CYP2D6 (0.46) | SLC6A3 | |
| SCHEMBL13799659 | 0.89 | SLC6A3 (0.40) | SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315483-B2 | Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315483-B2 | Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20140336387-A1 | SYNTHESIS OF DEUTERATED CATECHOLS AND BENZO[D][1,3]DIOXOLES AND DERIVATIVES THEREOF | CONCERT PHARMACEUTICALS, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336387-A1 | SYNTHESIS OF DEUTERATED CATECHOLS AND BENZO[D][1,3]DIOXOLES AND DERIVATIVES THEREOF | CONCERT PHARMACEUTICALS, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-8822498-B2 | Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822498-B2 | Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20090143432-A1 | Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20030187269-A1 | Novel process | SMITHKLINE BEECHAM PLC (GB) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187269-A1 | Novel process | TPO, KCNH3, HCCS | SLC6A3 3180/4885 |
| US-20140336387-A1 | SYNTHESIS OF DEUTERATED CATECHOLS AND BENZO[D][1,3]DIOXOLES AND DERIVATIVES THEREOF | COMT, DRD2, DRD3 | SLC6A3 21/4885 |
| US-20090143432-A1 | Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof | COMT, DRD2, DRD3 | SLC6A3 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.